Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › cervical squamous cell carcinoma

Cervical squamous cell carcinoma

Part of Cancer

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for cervical squamous cell carcinoma

15 trials tracked for cervical squamous cell carcinoma: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 1504 citations.

15Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 3 Phase 2 10 Phase 1 2
  1. Phase 3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed · 1,504 cited
  2. Phase 3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed
  3. Phase 3 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Completed
  4. Phase 2 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed
  5. Phase 2 Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix Completed
  6. Phase 2 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
Show 9 more trials
  1. Phase 2 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
  2. Phase 2 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed
  3. Phase 2 Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer Completed
  4. Phase 2 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed
  5. Phase 2 Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
  6. Phase 2 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed
  7. Phase 2 FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Completed
  8. Phase 1 Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Completed
  9. Phase 1 Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Cervical squamous cell carcinoma: what the trials found

Treatment options for cervical squamous cell carcinoma include the use of bevacizumab, which showed a progression-free survival greater than 6 months in approximately 23.9% of patients 10. Bevacizumab was also evaluated in a larger cohort as part of established protocols 1.

Surgical interventions include Extraperitoneal laparoscopic lymphadenectomy (EPLND) 2. Additionally, Cisplatin is an established treatment modality for this condition 3.

Recent results — preliminary, needs further review

  • Ipilimumab was evaluated in a Phase 2 trial 4.
  • Paclitaxel Albumin-Stabilized Nanoparticle Formulation was investigated in a Phase 2 study 5.
  • Filgristim was studied regarding Grade 3 or higher adverse events during treatment 6.
  • Ferumoxtran-10 was evaluated for its ability to detect biopsy-proven disease outside of abdominal and pelvic lymph nodes via PET/CT 7.
  • Paclitaxel was assessed in a Phase 2 trial 8.

For the clinician treating this condition

  • Bevacizumab is an established option, with a recorded progression-free survival rate of over 6 months in approximately 23.9% of patients 10.
  • Cisplatin and Extraperitoneal laparoscopic lymphadenectomy (EPLND) are established interventions for managing cervical squamous cell carcinoma [2, 3].

AI synthesis of 9 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review discusses HPV-associated head and neck and cervical squamous cell carcinoma without reporting specific outcomes
Allergy & Immunology Sys. Review
Narrative review discusses HPV-associated head and neck and cervical squamous cell carcinoma without reporting specific outcomes Doctors Find Hidden Pattern in HPV Cancers That Changes Treatment
This narrative review addresses patients with HPV-associated tumors involving head and neck squamous cell carcinoma and squamous cell carcin…
HPV cancers in the head and neck hide from the immune system differently than cervical cancers, explaining why some patients respond better …
Frontiers May 5, 2026
Cadonilimab therapy in cervical cancer associated with new-onset type 1 diabetes and diabetic ketoacidosis in a case report
Diabetes & Endocrinology Sys. Review
Cadonilimab therapy in cervical cancer associated with new-onset type 1 diabetes and diabetic ketoacidosis in a case report A Cancer Drug Triggered Sudden Diabetes in an 81-Year-Old
This systematic review includes a case report of an 81-year-old female with cervical squamous cell carcinoma who developed diabetic ketoacid…
A powerful cancer drug can switch off the body's insulin supply almost overnight, causing sudden, life-threatening diabetes in patients with…
Frontiers Apr 16, 2026

Research across Cancer

Related studies from across the Cancer family.

EGFR and TP53 mutations linked to worse survival in sinonasal squamous cell carcinoma
ENT (Otolaryngology) Meta-analysis
EGFR and TP53 mutations linked to worse survival in sinonasal squamous cell carcinoma Genetic markers linked to survival in sinonasal squamous cell carcinoma
A meta-analysis of 25 retrospective cohort studies including 1194 patients with sinonasal squamous cell carcinoma found that EGFR and TP53 m…
Specific genetic mutations and protein levels can help doctors predict how patients with certain head and neck cancers will respond to treat…
Jul 25, 2026
Diverse therapeutic approaches including immunotherapy are utilized for patients with occult squamous cell carcinoma
Allergy & Immunology Meta-analysis
Diverse therapeutic approaches including immunotherapy are utilized for patients with occult squamous cell carcinoma Men and women show different patterns in squamous cell carcinoma
This systematic review of case reports examines clinical characteristics and treatment strategies for patients with occult squamous cell car…
New data shows that men and women experience different locations for lymph node spread in certain types of skin cancer.
Frontiers Jul 25, 2026
Actinic keratosis increases melanoma risk while alcohol consumption is associated with lower squamous cell carcinoma risk
Genetics & Precision Medicine Meta-analysis
Actinic keratosis increases melanoma risk while alcohol consumption is associated with lower squamous cell carcinoma risk Actinic Keratosis Linked to Higher Risk of Melanoma
This meta-analysis of genome-wide association studies evaluates causal relationships between 11 modifiable risk factors and skin cancers. Th…
New research identifies a link between actinic keratosis and melanoma risk while highlighting potential new targets for skin cancer treatmen…
Frontiers Jul 8, 2026
Sugar sweetened beverages and orange juice are associated with increased risk of several cancer types
Nutrition & Obesity Medicine Sys. Review
Sugar sweetened beverages and orange juice are associated with increased risk of several cancer types Sugar sweetened drinks may increase risk of several cancer types
This meta-analysis of 51 cohort studies evaluates the link between sugar sweetened beverages (SSBs), artificially sweetened beverages (ASBs)…
New research suggests a link between sugar-sweetened beverages and an increased risk of certain cancers, including pancreatic and colorectal…
medRxiv Jul 7, 2026
EGFR inhibitors show reproducible activity and manageable toxicity in locally advanced or metastatic anal squamous cell carcinoma
Oncology Meta-analysis
EGFR inhibitors show reproducible activity and manageable toxicity in locally advanced or metastatic anal squamous cell carcinoma EGFR Inhibitors Show Activity in Advanced Anal Squamous Cell Carcinoma
This meta-analysis of 404 patients evaluated EGFR inhibitors (cetuximab and panitumumab) for anal squamous cell carcinoma. The analysis foun…
New analysis shows that EGFR inhibitors like cetuximab and panitumumab may improve response rates for patients with advanced anal squamous c…
Jul 5, 2026
Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation
Drug Pipeline Guideline
Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation New Treatment Strategy Shows Promise for Lung Squamous Cell Carcinoma
This case report describes a patient with stage IA2 lung squamous cell carcinoma and an ERBB2 exon 20 p.G776V mutation treated with trastuzu…
A new treatment plan using trastuzumab deruxtecan and pyrotinib showed promising results for a patient with a specific lung cancer mutation.
Frontiers Jun 21, 2026
Transitioning from static TNM staging to a multidimensional, adaptive treatment model integrating genomics and immunology for HPV-associated OPSCC
Allergy & Immunology Sys. Review
Transitioning from static TNM staging to a multidimensional, adaptive treatment model integrating genomics and immunology for HPV-associated OPSCC Doctors are shifting from static staging to adaptive care for HPV throat cancer
This narrative review discusses the evolving management of HPV-associated oropharyngeal squamous cell carcinoma. The authors argue for trans…
Medical teams are moving away from old staging rules toward a new model that uses genomics and immunology for precise care.
Frontiers Jun 1, 2026
Systematic review and meta-analysis of survival outcomes in HPV-independent versus HPV-associated cervical adenocarcinoma
Oncology Meta-analysis
Systematic review and meta-analysis of survival outcomes in HPV-independent versus HPV-associated cervical adenocarcinoma One Type of Cervical Cancer Is Far More Dangerous Than Others
This systematic review and meta-analysis synthesized comparative studies on HPV-independent and HPV-associated cervical adenocarcinoma. It f…
A large new analysis reveals that women with HPV-negative cervical adenocarcinoma face nearly three times the risk of death compared to thos…
Frontiers May 8, 2026
Meta-analysis of sirolimus for cutaneous squamous cell carcinoma in kidney transplant recipients
Dermatology Meta-analysis
Meta-analysis of sirolimus for cutaneous squamous cell carcinoma in kidney transplant recipients Sirolimus lowers skin cancer risk in kidney transplant patients
This meta-analysis of four randomized trials in kidney transplant recipients with prior cutaneous squamous cell carcinoma found that switchi…
A review of studies shows switching to sirolimus can cut skin cancer rates, but it may cause more side effects.
May 2, 2026
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
Oncology Meta-analysis
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
May 1, 2026
SBRT plus atezolizumab shows activity in metastatic cervical cancer
OB/GYN & Women's Health Phase II
SBRT plus atezolizumab shows activity in metastatic cervical cancer Radiation plus immune therapy helps some patients with advanced cervical cancer survive longer
This prospective phase II trial evaluated SBRT followed by atezolizumab in 21 patients with metastatic, recurrent, or persistent cervical ca…
A small trial found that adding immune therapy to radiation helped some patients with advanced cervical cancer keep their disease stable for…
May 1, 2026
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
Pulmonology & Critical Care Meta-analysis
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
May 1, 2026